Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review

Empagliflozin is an oral hypoglycemic drug belonging to the class of SGLT2 inhibitors. It acts on transporters in the proximal tubules of the kidneys to reduce blood glucose by promoting glucose excretion in the urine. This review examines various analytical method development strategies for Empagliflozin, with a focus on Quality by Design (QbD) approaches.

Empagliflozin, Antidiabetic Drug, Analytical Method, QbD, ICH.

1. Ndefo, U.A.; Anidiobi, N.O.; Basheer, E.; Eaton, A.T. (2015). Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. Pharm. Ther. 40, 364–368. [Google Scholar] [Crossref]

2. Chen, L.H.; Leung, P.S. (2013). Inhibition of the sodium glucose co-transporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes. Metab. 15, 392–402. [Google Scholar] [Crossref]

3. Scheen, A.J. (2014). Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Clin. Pharmacokinet. 53, 213–225. [Google Scholar] [Crossref]

4. Chawla, G.; Chaudhary, K.K. (2019). A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab. Syndr. Clin. Res. Rev. 13, 2001–2008. [Google Scholar] [Crossref]

5. Chatterjee, S.; Khunti, K.; Davies, M. (2016). Optimizing management of glycaemia. Best Pract. Res. Clin. Endocrinol. Metab. 30, 397–411. [Google Scholar] [Crossref]

6. Patil AS, Pethe AM. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Qual Assur. 4: 13-19 [Google Scholar] [Crossref]

7. Vogt FG, Kord AS.(2011). Development of quality by design analytical methods. J Pharm Sci. 100: 797-812. [Google Scholar] [Crossref]

8. Shaik Bima Benazir, Jorige Archana, Mogili Sumakanth (2021). Method Development and Validation of Empagliflozin in Bulk and Pharmaceutical Dosage Form using UV Spectroscopy. Asian Journal of Pharmaceutical Analysis. Vol 11(2): 123-126. [Google Scholar] [Crossref]

9. Joanna Wittchckind Manoel, Martin Steppe (2020). The application of quality by design in the development of the liquid chromatography method to determine Empagliflozin in the presence of its organic impurities. Royal soci. of chem, 10: 7313-7320. [Google Scholar] [Crossref]

10. Prerana Prakash Bhavsar, Subodh Anil Gangurde (2025). RP-HPLC Method Development & Validation of Empagliflozin by using QbD Approach. RJPT, Vol 18(11). [Google Scholar] [Crossref]

11. N. Padmaja, Tegene Desalegn (2018). New validated RP-HPLC method for the estimation of empagliflozin in human plasma. IJPSR, Vol. 9(11), 4885-4889. [Google Scholar] [Crossref]

12. Yogeshwari Jambhulkar, Nitu Madan (2024). Empagliflozin: RP-HPLC based analytical method development and validation. European journal Pharmaceutical and Medical Research, 11(12):291-297. [Google Scholar] [Crossref]

13. https://doi.org/10.71152/y05skn43 (2025 )Analytical method development and validation of emphagliflozin by RP-HPLC . Int. Jour. Of pharma Medix india. 3(3): [Google Scholar] [Crossref]

14. Dr. K M Khairul Alam, Tanbin Jahan Ferdousy (2023). Development and Validation of an RP-HPLC Method for Determination of Empagliflozin in Empagliflozin Tablet. International Journal of Innovative Science and Research Technology, 8(3):3686-3693. [Google Scholar] [Crossref]

15. Sarfaraj Ahamad Khan, Dr. Chandanam Sreedhar (2019). New analytical method development and validation of empagliflozin (anti-diabetic) drug by rp-hplc method in bulk and pharmaceutical dosage form. IJRAR, 6(1):475-483. [Google Scholar] [Crossref]

16. Madhavi, S., and A. P. Rani. (2017). Development and Validation of UPLC Method for the Simultaneous Estimation of Saxagliptin and Dapagliflozin in Tablet Dosage Form. Asian Journal of Pharmaceutical and Clinical Research, 10(11): 247–251. [Google Scholar] [Crossref]

17. Nutan B. Raut, Padmanabh B. Deshpande (2022). Stability indicating HPTLC method development and validation for determination of empagliflozin in bulk drug and tablet dosage form, ejpmr, 2022, 9(7), 443-448. [Google Scholar] [Crossref]

18. Vineeta Khanvilkar, Gayatri Vinchurkar (2025). Stability indicating assay method for estimation of Empagliflozin using HPTLC, JMPACO, (14)1: 7017-3023 [Google Scholar] [Crossref]

19. Manojkumar Munde, Nilesh Kulkarni. (2023). A novel validated stability indicating method for quantification of Empagliflozin in bulk and marketed formulation by hptlc applying experimental design approach. Indian Drugs, 60: 66-75. [Google Scholar] [Crossref]

20. Jagadeesh, M., & Kumar, G. (2022). Development and validation of empagliflozin in human plasma using nevirapine as internal standard by liquid chromatography-tandem mass spectrometry. International Journal of Health Sciences, 6(S6), 272–281. https://doi.org/10.53730/ijhs.v6nS6.9683 [Google Scholar] [Crossref]

21. Sushil Kumar Singh, Amol S Gaikwad (2025). Derivatization Method as a Residual Solvent of Acetic Acid by GC-MS Method in Empagliflozin Drug Substance: Development and Evaluation, RJPT, 18(6). [Google Scholar] [Crossref]

22. Prabh Simran Singh, Gagan Shah, (2011). Analytical Method Development and Validation, Journal of Pharmacy Research, 4(7), 2330-2332. [Google Scholar] [Crossref]

23. Ravisankar P, Gowthami S, and Devala Rao G, (2014). A review on analytical method development, Indian journal of research in pharmacy and biotechnology, 2, 1183-1195. [Google Scholar] [Crossref]

24. Shushila DC, Deepa MD (2022). Analytical methods validation: a brief review. WJARR. ;16(2):10–12 [Google Scholar] [Crossref]

25. Nilam B, Vijaya B (2024). A review on analytical methods validation. IJSRST. 11(1):1–4 [Google Scholar] [Crossref]

26. Jaha SM (2017). Validation in pharmaceutical industry: cleaning validation – a brief. Int J Pharm Sci. 5(1):1–3. [Google Scholar] [Crossref]

27. Indian Pharmacopoeia (IP), (2022), Volume IV, General Chapter: 41 — Validation of Analytical Procedures. [Google Scholar] [Crossref]

28. Toomula N, Kumar A, Kumar SD, Bheemidi VS. (2011). Development and validation of analytical methods for pharmaceuticals. J Anal Bioanal Tech. 2:127. [Google Scholar] [Crossref]

29. Kadam VR, Patil M, Pawar VV, Kshirsagar S. (2017). A review on: Quality by design (QbD). Asian Journal of Research in Pharmaceutical Sciences. 7(4):197-204. [Google Scholar] [Crossref]

30. Fukuda IM, Pinto CFF, Moreira CdS, Saviano AM, Lourenço FR. (2018). Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Brazilian journal of pharmaceutical sciences. 54: e01006. [Google Scholar] [Crossref]

31. Beg S, Hasnain MS, Rahman M, Swain S.(2019). Introduction to quality by design (QbD): fundamentals, principles, and applications. Pharmaceutical quality by design: Elsevier; p. 1-17. [Google Scholar] [Crossref]

32. Waterman KC. (2011). The application of the accelerated stability assessment program (ASAP) to quality by design (QbD) for drug product stability. AAPS PharmSciTech. 12:932-7. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities